Iridex Stock Today
| IRIX Stock | USD 1.15 0.04 3.36% |
PerformanceVery Weak
| Odds Of DistressAbove Average
|
IRIDEX is trading at 1.15 as of the 8th of May 2025; that is 3.36% down since the beginning of the trading day. The stock's open price was 1.19. IRIDEX has more than 60 % chance of experiencing financial distress in the next few years of operation. It also generated negative returns for investors over the last 90 days. The performance scores are derived for the period starting the 8th of April 2025 and ending today, the 8th of May 2025. Click here to learn more.
Business Domain Health Care Equipment & Services | IPO Date 15th of February 1996 | Category Healthcare | Classification Health Care |
IRIDEX Corporation, an ophthalmic medical technology company, provides therapeutic based laser systems, delivery devices, and consumable instrumentation to treat sight-threatening eye diseases in ophthalmology. IRIDEX Corporation was incorporated in 1989 and is headquartered in Mountain View, California. The company has 16.79 M outstanding shares of which 269.92 K shares are currently shorted by private and institutional investors with about 2.17 trading days to cover. More on IRIDEX
Moving together with IRIDEX Stock
Moving against IRIDEX Stock
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
IRIDEX Stock Highlights
| CEO President | David Bruce | ||||
| Business Concentration | Health Care Equipment & Supplies, Health Care Equipment & Services, Health Care, NASDAQ Composite, NASDAQ Composite Total, NASDAQ Health Care, Health Care, Health Care Equipment & Supplies, Medical Devices, Healthcare (View all Sectors) | ||||
| Average Analyst Recommendation | |||||
Debt LevelsIRIDEX can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand IRIDEX's financial leverage. It provides some insight into what part of IRIDEX's total assets is financed by creditors.
| |||||
IRIDEX (IRIX) is traded on NASDAQ Exchange in USA. It is located in 1212 Terra Bella Avenue, Mountain View, CA, United States, 94043 and employs 93 people. IRIDEX is listed under Health Care Equipment & Supplies category by Fama And French industry classification. The company currently falls under 'Micro-Cap' category with a current market capitalization of 19.81 M. IRIDEX conducts business under Health Care Equipment & Supplies sector and is part of Health Care industry. The entity has 16.79 M outstanding shares of which 269.92 K shares are currently shorted by private and institutional investors with about 2.17 trading days to cover.
IRIDEX currently holds about 17.97 M in cash with (7.29 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.12.
Check IRIDEX Probability Of Bankruptcy
Ownership AllocationIRIDEX has a total of 16.79 Million outstanding shares. IRIDEX secures noticeable amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares. Please note that no matter how many assets the company holds, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check IRIDEX Ownership Details
IRIDEX Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| State Street Corp | 2024-12-31 | 44.7 K | |
| Long Focus Capital Management, Llc | 2024-12-31 | 38.2 K | |
| Bank Of New York Mellon Corp | 2024-12-31 | 31.5 K | |
| Susquehanna International Group, Llp | 2024-12-31 | 30.9 K | |
| Northern Trust Corp | 2024-12-31 | 27.2 K | |
| Dimensional Fund Advisors, Inc. | 2024-12-31 | 24.4 K | |
| Bb&t Corp. | 2024-12-31 | 13 K | |
| Ubs Group Ag | 2024-12-31 | 12.3 K | |
| Hightower Advisors, Llc | 2024-12-31 | 10.1 K | |
| Paragon Assoc & Paragon Assoc Ii Jv | 2024-12-31 | 1000 K | |
| Vanguard Group Inc | 2024-12-31 | 561.1 K |
IRIDEX Historical Income Statement
IRIDEX Stock Against Markets
IRIDEX Corporate Management
| Leigh Salvo | Head Relations | Profile | |
| Patrick Mercer | Chief Officer | Profile | |
| Fuad Ahmad | Interim Officer | Profile | |
| Bassem BouHabib | Vice Sales | Profile | |
| Romeo Dizon | Chief Officer | Profile |
Additional Tools for IRIDEX Stock Analysis
When running IRIDEX's price analysis, check to measure IRIDEX's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy IRIDEX is operating at the current time. Most of IRIDEX's value examination focuses on studying past and present price action to predict the probability of IRIDEX's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move IRIDEX's price. Additionally, you may evaluate how the addition of IRIDEX to your portfolios can decrease your overall portfolio volatility.